Viking Therapeutics VKTX Prepaid Clinical Trial And Preclinical Study Costs
Prepaid Clinical Trial And Preclinical Study Costs at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept vktx:PrepaidClinicalTrialAndPreclinicalStudyCosts.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's prepaid clinical trial and preclinical study costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's prepaid clinical trial and preclinical study costs?
- Viking Therapeutics (VKTX) reported prepaid clinical trial and preclinical study costs of $4.02M in Q1 2026.
- How has Viking Therapeutics's prepaid clinical trial and preclinical study costs changed year-over-year?
- Viking Therapeutics's prepaid clinical trial and preclinical study costs decreased by 69.8% year-over-year, from $13.3M to $4.02M.
- What is the long-term trend for Viking Therapeutics's prepaid clinical trial and preclinical study costs?
- Over 5 years (2020 to 2025), Viking Therapeutics's prepaid clinical trial and preclinical study costs has grown at a 2.0% compound annual growth rate (CAGR), from $7.28M to $8.05M.
- What does prepaid clinical trial and preclinical study costs mean?
- This metric represents payments made in advance to vendors, contract research organizations, or clinical sites for future research and development activities. It reflects the company's commitment to upcoming clinical trials and preclinical studies before the associated services are fully rendered. Tracking this balance provides insight into the company's near-term R&D pipeline activity and cash outflow timing for drug development programs.